Tarzana Treatment Centers, Inc.
Welcome,         Profile    Billing    Logout  
 9 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oliveto, Alison
NCT06233799: Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Recruiting
3
360
US
extended-release naltrexone (XR-NTX), Vivitrol, extended release bupropion (BUP-XL) tablets (BUP-XL), Wellbutrin, iPLB, Placebo injections, oPLB, Placebo tablets
National Institute on Drug Abuse (NIDA)
Methamphetamine-dependence, Methamphetamine Abuse
10/26
04/27
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder

Recruiting
2
426
US
Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo
University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
03/25
09/26
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
NCT06055309: Behavioral Pharmacology of Cannabis in Older Adults

Not yet recruiting
1
5
US
Cannabis (up to three doses)
University of Arkansas
Health Services for the Aged
12/24
12/24
Mooney, Larissa J
RXR, NCT06023459: Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings

Not yet recruiting
3
144
US
Injectable extended-release buprenorphine, XR-BUP (Brixadi), Sublingual buprenorphine-naloxone, SL-BUP
Yih-Ing Hser, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), The Emmes Company, LLC, University of California, Los Angeles, RAND, Cornell University, Oregon Health and Science University, University of Illinois at Chicago, University of Washington, West Virginia University
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
11/24
12/24
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Completed
2
333
US
AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo
Aelis Farma, National Institute on Drug Abuse (NIDA)
Marijuana Abuse
04/24
07/24
PtDA-MAT, NCT03568552: Patient Decision Aid for Opioid Use Disorder

Recruiting
N/A
5400
US
Patient Decision Aid
University of California, Los Angeles
Opioid Use Disorder
08/24
08/24
Hser, Yih-Ing
RXR, NCT06023459: Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings

Not yet recruiting
3
144
US
Injectable extended-release buprenorphine, XR-BUP (Brixadi), Sublingual buprenorphine-naloxone, SL-BUP
Yih-Ing Hser, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), The Emmes Company, LLC, University of California, Los Angeles, RAND, Cornell University, Oregon Health and Science University, University of Illinois at Chicago, University of Washington, West Virginia University
Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
11/24
12/24
NCT04418453: Rural MOUD Telemedicine in Primary Care Phase 1

Completed
N/A
36762
US
Integration of telemedicine for MOUD in primary care
University of California, Los Angeles, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
07/21
11/21
PtDA-MAT, NCT03568552: Patient Decision Aid for Opioid Use Disorder

Recruiting
N/A
5400
US
Patient Decision Aid
University of California, Los Angeles
Opioid Use Disorder
08/24
08/24
Bachrach, Kenneth M
NCT03787628: Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

Completed
2
35
US
Cannabidiol (CBD) 600 mg, Placebo
University of California, Los Angeles, National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
03/24
03/24
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26
Rakhmanov, Tolib M
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
07/26
12/26

Download Options